Audit of the outcome of pregnancy in diabetic women in Soweto, South Africa, 1992 - 2002 by Huddle, Kenneth R
ORIGINAL ARTICLES
789
October 2005, Vol. 95, No. 10  SAMJ
Great strides were made during the last century in the
management of diabetes in pregnancy. Before the discovery of
insulin in 1921 the outlook for the diabetic mother and her
fetus was abysmal.1 With the advent of insulin, an emphasis on
a team approach to care, improved methods of fetal
surveillance, and a focus on metabolic normalisation brought
about by intensive insulin regimens and home glucose
monitoring, the outlook for both the diabetic mother and her
offspring has improved dramatically, approaching that of the
non-diabetic pregnancy.2,3 However, this success story, which is
the experience of many developed countries, is not shared to
any great extent in sub-Saharan Africa, where the resources for
diabetes management are often lacking, resulting in a situation
reminiscent of the pre-insulin era. Reports from this region on
the management of diabetes in pregnancy are few, the numbers
are small, and the perinatal mortality figures are high.4-8
Against this background, a combined specialist clinic for
pregnant diabetic women was established in 1983 at Chris
Hani Baragwanath Hospital (CHBH), a 3 000-bed teaching
hospital linked to the University of the Witwatersrand. The
initial experience at this clinic has been reported previously.9
CHBH performs more than 1 500 deliveries per month, and
serves the people of Soweto, a large, sprawling township
situated on the outskirts of Johannesburg whose population of
several million is almost entirely of African ethnic origin. The
majority of the inhabitants are poor and indigent and
unemployment is rife. The AIDS epidemic has had devastating
effects on this community for over a decade.
The following report covers the period 1992 - 2002.
Design and methods
The combined specialist clinic comprised physician,
obstetrician, paediatrician, and diabetes nurse educator. The
study population included women almost exclusively of
African ethnic origin drawn mainly from Soweto. The diabetes
was classified as follows.
Diabetes was considered gestational if the diagnosis was
made during pregnancy in women referred because of the
presence of risk factors for diabetes, i.e. persistent glycosuria,
strong family history, previous unexplained perinatal loss, and
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Objective. To audit the outcome of pregnancy among diabetic
black women in Soweto following the introduction of a
specialised service.
Design and methods. An analysis of patients’ records was
conducted for the period 1992 - 2002. Maternal characteristics,
aspects of treatment and its complications, mode of delivery
and perinatal outcome are reported. The incidence of
postpartum glucose intolerance in women with gestational
diabetes was assessed.  Major outcomes from this study are
compared with those of an earlier study conducted from 1983
to 1992.
Results. A total of 733 diabetic pregnancies was managed over
11 years: 348 women had gestational diabetes, 172 had type 1
diabetes and 213 had type 2 diabetes. Insulin was used in all
but 23 women. Mean (± standard deviation (SD)) capillary
blood glucose levels varied between 5.7 (± 0.72) and 6.2 (± 0.95)
mmol/l in the 3 groups. Severe maternal hypoglycaemia was
most common in the type 1 diabetes group (14%).   Mean (±
SD) neonatal weight varied between 2 922.3 g (± 753) and 
3 073.3 g (± 727). Caesarean section rates exceeded 60% in all 3
groups. Overall, 13.1% of women had hypertension, 31.3% of
whom had proteinuric hypertension. There were no cases of
progressive pre-eclampsia. The combined perinatal mortality
(PMN) rate was 3.7%, compared with 15.6% in the ‘control’
group.  Major congenital malformations occurred in 11
pregnancies (1.5%).  There were 2 maternal deaths. Postpartum
impaired glucose tolerance/diabetes occurred in 25.9% of
women with gestational diabetes.  Combining the 2 studies
(1983 - 1992 and 1992 - 2002), 1 087 pregnancies were managed
over 20 years using a similar protocol. There were no
significant differences in major outcomes between the 2
studies.    The overall PMN of 4.5% is significantly lower than
that of the combined ‘control’ group (19.9%).  Postpartum
glucose intolerance was documented in 28.5% of women.
Conclusions. The institution of a specialised service for
pregnant diabetic women from Soweto for a sustained period
of 20 years proved feasible and was of significant benefit. The
interventions, centred around a diabetes nurse educator, were
relatively simple and easy to implement.  Late
presentation/referral of patients remains a problem.
Persistence of glucose intolerance postpartum in women with
gestational diabetes was common and provides an opportunity
for preventive measures to be introduced.
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previous gestational diabetes. Diagnosis was confirmed using
the 100 g oral glucose tolerance test (OGTT) (National Diabetes
Data Group criteria).10
Diabetes was considered pregestational if the diabetes was
present before conception. This group was further divided into
type 1 and type 2 diabetes groups depending on the
pregestational use/non-use of insulin. 
After some time it became clear that it was necessary to
include an additional category of patients, a ‘control’ group,
which refers to those women who, because of late referral or
presentation, were unable to receive more than 2 weeks of
intensive management before delivery. This group reflects the
deficiencies that exist in our referral system, but affords us the
opportunity to document the effect of uncontrolled diabetes on
pregnancy outcome. It is important to note that in all instances
of viable pregnancy in the ‘control’ group rapid attempts to
achieve metabolic control were made and delivery was
performed as soon as fetal maturity was confirmed.
All women were hospitalised initially for clinical and
biochemical assessment, ultrasonographic examination to
assess gestational age and the presence of fetal abnormalities,
and determination of treatment. All oral hypoglycaemic agents
were withdrawn at presentation. Diabetic retinopathy was
assessed using a standard ophthalmoscope after the pupils had
been dilated using a short-acting mydriatic agent
(tropicamide). Diabetic nephropathy was diagnosed if ‘dipstix’-
positive proteinuria (protein ≥ 0.3 g/l) was found on repeated
testing, in the absence of urinary tract infection or other renal
disease. Hypertension was diagnosed if the blood pressure was
persistently elevated above 140/90 mmHg (Korotkoff phase V);
proteinuric hypertension was diagnosed if persistent ‘dipstix’-
positive proteinuria developed in association with
hypertension in patients who had had no evidence of
proteinuria at presentation.
Patients were taught home blood glucose monitoring by the
nurse educator – fingerprick capillary blood samples were
obtained using lancets and blood glucose levels were read
visually using Haemo-glukotest 20-800R strips (Roche
Diagnostics GmbH, Mannheim, Germany).  Fasting,
preprandial and 2-hour postprandial (substituted more recently
with 1-hour postprandial) blood glucose levels were recorded
in hospital and at home. Glycated haemoglobin (HbA1c) (Tina-
quant HbA1c) immunological assay, Roche Diagnostics GmbH,
Mannheim, Germany – normal range 4.8 - 6%) was measured
at presentation and monthly thereafter from 1995 onwards. All
subjects followed an 1 800 - 2 000 kcal complex carbohydrate
diabetic diet (comprising 60% carbohydrates, 25% fat, 15%
protein) divided into 3 main meals and between-meal and late-
night snacks.
Insulin therapy was begun if the fasting blood glucose level
exceeded 4 mmol/l and/or the pre-meal and 2-hour (or 1-
hour) postprandial levels rose above 7 mmol/l. Multiple doses
of short- and intermediate-acting human insulins were used.
The aim of therapy was to maintain the blood glucose levels
between 4 and 7 mmol/l and the HbA1c levels < 7% without
inducing severe hypoglycaemic reactions.
After initial assessment in hospital, patients returned
fortnightly for follow-up until 32 weeks’ gestation and then
weekly until 37 weeks when they were readmitted. A full
clinical assessment was made at each visit, the results of home
blood glucose monitoring were recorded and the technique
checked, and adjustments in treatment were made accordingly.
Ultrasound examinations were repeated at intervals to assess
fetal growth, fetal abnormalities, and liquor volume.
Predelivery management in hospital consisted of frequent
clinical assessments and corrections of deviations from
glycaemic control targets. Fetal growth and wellbeing were
monitored using serial ultrasound and non-stress tests. The
timing and mode of delivery were dictated by obstetric factors
and by the duration and degree of glycaemic control.
Amniocentesis was performed in cases of preterm delivery to
assess fetal lung maturity, and in women at risk for Down’s
syndrome. During labour or caesarean section diabetes was
controlled using dextrose-insulin infusions with frequent
monitoring of capillary blood glucose samples. Insulin therapy
was terminated in the immediate postpartum period and blood
glucose monitoring was recommenced. Usually, insulin was
restarted in patients with type 1 diabetes on day 2 - 3
postpartum at the pre-pregnancy doses. The treatment of the
remaining groups of patients was dictated by the results of the
blood glucose profiles. Gestational diabetic women were
recalled at 6 weeks for a 75 g OGTT (WHO World Health
Organization criteria for non-pregnant adults).
Neonates were assessed by the paediatric staff for the
presence of clinical and/or biochemical complications/
abnormalities and managed accordingly. Methods of
contraception were discussed with each patient so that
informed decisions could be made.
Statistical comparisons were made using analysis of variance
(ANOVA), Student’s t-test and chi-squared tests.
Results
Maternal profiles (Table I)
A total of 733 pregnancies were managed over 11 years. The
majority of women had gestational diabetes mellitus (GDM).
Most of the women with type 1 (type 1 DM) and type 2
diabetes mellitus (type 2 DM) presented towards the middle
and end of the second trimester respectively; women with
GDM presented well into the third trimester.  Overall, 96
women (13.1%) had hypertension: 30 (31.3%) had proteinuric
hypertension, 19 (19.8%) were classified as gestational
hypertension, 33 (34.4%) as chronic hypertension, 6 (6.3%) were
unclassified, and 8 (8.3%) had hypertension superimposed on
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diabetic nephropathy.  There were no instances of progressive
pre-eclampsia with coagulatory and/or liver dysfunction, nor
were there any cases of eclampsia. Methyldopa was used as
monotherapy in 56 (58.3%) of the hypertensive patients,
methydopa plus hydralazine in 17 (17.7%), and 23
hypertensive women (24%) were managed without
pharmacological treatment. Diabetic retinopathy and/or
nephropathy were most frequent in the patients with type 1
DM. Retinopathy was present in 56 (7.6%) of women overall;
with the exception of 1 case of proliferative retinopathy, all
were of background type. There was 1 instance of acute
deterioration of visual acuity in a woman with type 1 DM and
background retinopathy – she developed macular oedema
associated with a 5.4% drop in her HbA1c level over a 3-week
period. Her condition settled without intervention. Nephro-
pathy was diagnosed in 18 patients (2.5%) overall. Ten had
persistent proteinuria without hypertension or elevated serum
creatinine level, and 8 had persistent proteinuria with
associated hypertension, 2 of whom also had raised serum
creatinine levels (117 and 213 µmol/l respectively). The sole
perinatal loss among the women diagnosed with diabetic
nephropathy was a stillbirth to a woman with persistent
proteinuria alone.
There were 2 maternal deaths in this study. The first, a 36-
year-old woman with type 2 DM, died at home at 21 weeks’
gestation of unknown cause. She was obese (109 kg) and on
high doses of insulin (230 units/day). She had had a  severe
hypoglycaemic reaction several days beforehand for which she
was counselled, and her insulin doses were reduced. No
autopsy was performed. The second death involved a 34-year-
old woman with type 2 DM. The woman died at home at 19
weeks’ gestation. She was on 84 units of insulin per day and
weighed 82 kg. There had been no preceding episodes of
hypoglycaemia. No autopsy was performed. The cause of
death is unknown.
Aspects of treatment and treatment complications
(Table II)
Diet was used as monotherapy in 17 patients (4.9%) with GDM
and in 5 women (2.3%) with type 2 DM.  The remaining
patients were treated with diet and insulin.  In the majority of
women insulin requirements increased progressively with
increasing gestational age.  The mean capillary glucose levels
in all 3 groups of women approximated 6.0 mmol/l. The mean
HbA1c (measured from 1995 onwards and within 4 weeks of
delivery) was below 7.0% in all 3 groups of patients. The mean
± SD pre-delivery HbA1c levels decreased significantly from the
HbA1c levels at first booking in all 3 groups: from 7.1 ± 1.7% to
Table I. Summary of maternal characteristics 
Gestational Pregestational diabetes
diabetes Type 1 diabetes Type 2 diabetes
Pregnancies (N (%)) 348 (47.5) 172 (23.5) 213 (29)
Age (yrs) (mean ± SD) 33.9 ± 5.2* 30.5 ± 6.2 34.3 ± 5.0†
Gestational age at presentation 
(wks) (mean ± SD) 28.3 ± 6.4*‡ 18.5 ± 7.1 21.4 ± 7.2†
Duration of diabetes (yrs) (mean ± SD) - 6.0 ± 4.2 3.7 ± 3.1
Hypertension (N (%)) 50 (14.4) 23 (13.4) 23 (10.9)
Retinopathy (N (%)) 5 (1.4)*‡ 30 (17.4) 21 (9.9)§
Nephropathy (N (%)) 1 (0.3)* 13 (7.6) 4 (1.9)†
*p < 0.01 gestational v. type 1 diabetes.
†p < 0.01 type 2 diabetes v. type 1 diabetes.
‡p < 0.01 gestational v. type 2 diabetes.
§p < 0.03 type 2 diabetes v. type 1 diabetes.
Table II. Aspects of treatment and its complications 
Gestational Pregestational diabetes
diabetes Type 1 diabetes Type 2 diabetes
Total insulin dose/day (units)* (mean ± SD) 106.9 ± 60.7† 93.3 ± 43.7 114.5 ± 60.6§
Mean capillary blood glucose 
(mmol/l) (mean ± SD) 6.2 ± 0.95†‡ 5.7 ± 0.72 5.9 ± 0.84¶
HbA1c (%) at first booking (mean ± SD) 7.1 ± 1.7†‡ 8.2 ± 2.0 7.8 ± 2.0
HbA1c (%) at delivery (mean ± SD) 6.6 ± 1.2 6.8 ± 1.0 6.5 ± 1.0
Maternal hypoglycaemia (% of patients) 0.9†‡ 14 7¶
*At delivery.
†p < 0.01 gestational v. type 1 diabetes.
‡p < 0.01 gestational v. type 2 diabetes.
§p < 0.01 type 2 diabetes v. type 1 diabetes.
¶p < 0.03 type 2 diabetes v. type 1 diabetes.
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6.6 ± 1.2% (p = 0.0001) in the GDM group, from 8.2 ± 2.0% to
6.8 ± 1.0% (p < 0.00001) in the type 1 DM group, and from 7.8 ±
2.0% to 6.5 ± 1.0% (p < 0.00001) in the type 2 DM group.
Maternal hypoglycaemia (1 or more episodes) severe enough to
necessitate the administration of intravenous dextrose,
occurred significantly more often in women with type 1 DM
than in the other 2 groups. No maternal morbidity or mortality
was directly attributable to hypoglycaemia.   
Mode of delivery and perinatal outcome (Table III)
Caesarean section rates were similar in all 3 groups at just over
60%.   The gestational age at delivery was similar in all 3
groups at 37 weeks.  The mean birth weights approximated 
3 000 g for the 3 groups, with 9.6% of neonates weighing ≥ 4 kg
– 12.5% in the GDM group, 5.2% in the type 1 group, and 8.5%
in the type 2 group – the percentage being significantly higher 
(p = 0.02) in the GDM group than in the other 2 groups.  The
overall perinatal mortality for this study was 3.7% (37/1 000)
with no significant differences between the 3 groups. The 5
early neonatal deaths in the GDM group comprised the
following:  1 instance of birth asphyxia and respiratory distress
syndrome following premature rupture of membranes  (the
baby also had extra digits, undescended testes and choanal
atresia); 1 death due to premature delivery at 31 weeks
precipitated by the development of pre-eclampsia; 2 deaths due
to major congenital malformations; and 1 instance of Down’s
syndrome associated with congenital leukaemia. The causes of
the 2 early neonatal deaths in the type 2 DM group were not
defined; both babies had minor congenital abnormalities.
Overall, there were 11 (1.5%) major congenital abnormalities
including skeletal, neurological, cardiovascular, renal and
gastrointestinal defects (Table IV).  A total of 8 newborns (1.1%)
in the GDM and type 1 DM groups developed hyaline
membrane disease requiring ventilation. All were related to
premature delivery and were precipitated by pre-eclampsia 
(2 cases), premature rupture of membranes (2 cases), triplet
pregnancy (2 cases), twin pregnancy (1 case), and antepartum
haemorrhage (1 case). One of these 8 newborns died. (It is our
policy to use betamethasone in cases of anticipated premature
delivery to prevent respiratory distress syndrome.)
‘Control group’
The ‘control’ group comprised a total of 211 pregnancies: 170
women had GDM, 16 had type 1 DM, and 25 had type 2 DM.
The overall perinatal mortality rate in the ‘control’ group was
15.6%, with stillbirths accounting for 90% of deaths. There were
4 major congenital anomalies overall. No maternal deaths
occurred.
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Table III.  Mode of delivery and perinatal outcome 
Gestational Pregestational diabetes
diabetes Type 1 diabetes Type 2 diabetes
Live births (N) 344 172 214
Caesarean section (%) 61.8 63 61.5
Birth weight (g) (mean ± SD) 3 204.9 ± 657‡ 2 922.3 ± 753 3 073.3 ± 727§
Gestational age at delivery (wks) (mean ± SD) 37.0 ± 1.6 36.6 ± 2.0 37.0 ± 1.9
Neonatal hypoglycaemia (%) 3.5 5.8 7.5
Perinatal mortality (%)* 4.2 3.9 2.8
Stillbirths (N (%)) 10 (2.8) 7 (3.9) 4 (1.8)
Early neonatal deaths (N (%)) 5 (1.4) 0 2 (0.9)
Major congenital abnormalities (N (%)) 8 (2.3) 1 (0.6) 2 (0.9)
*Overall PNM for 3 groups = 3.7%.
†p < 0.01 gestational v. type 1 diabetes.
‡p < 0.04 gestational v. type 2 diabetes.
§p < 0.04 type 2 diabetes v. type 1 diabetes.
Table IV.    Major congenital malformations
Type of malformation
Gestational
diabetes
1 Holoprosencephaly; cleft lip and palate; absent
radius, tibia, fibula
2 Holoprosencephaly; microcephaly; single nostril;
small mouth; rocker-bottom feet
3 Skull defect with encephalocele; midline facial
defect
4 Small head; asymmetrical face; closed eye; low-
set ears; short neck; patent ductus arteriosus
5 Renal agenesis; hypoplastic lungs; anal atresia;
clubbed feet; short limbs
6 Cleft lip and palate
7 Imperforate anus
8 Choanal atresia; undescended testes; extra digits
Type 2 DM
1 Single cardiac ventricle; dextrocardia; patent
ductus arteriosus
2 Anencephaly
Type 1 DM
1 Ventricular septal defect; patent ductus
arteriosus; interrupted aortic arch; aberrant
subclavian artery
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Persistence of glucose intolerance in the GDM
group postpartum
Excluding the ‘control’ group, 29 women (8.3%) in the GDM
group had persistence of diabetes in the immediate
postpartum period, and 1 woman developed diabetes 1 year
postpartum. Of the remaining 318 women, 148 (46.5%)
returned for a 75 g OGTT – 88 (59.5%) were normal, 30 (20.3%)
had a diabetic OGTT, and 30 (20.3%) had impaired glucose
tolerance (IGT). Therefore, including the 170 women who did
not return for an OGTT, 25.9% of GDM women had evidence
of IGT (33%) or diabetes (67%) postpartum.
Discussion 
The data from this study show the benefits of prolonged
exposure to intensified management of diabetes in pregnancy
in a Third-World setting. The overall PNM of 3.7% in the
‘treated’ group of 733 pregnancies is significantly lower than
the 15.6% recorded in the ‘control’ group (p < 0.001).  The
combined PNM for these 2 groups is 6.3% which is
considerably lower than the rate reported in studies from other
African countries. There are few published studies from sub-
Saharan Africa and the numbers of enrolled patients are small.
In a review of 5 published African studies,4 PNM varied from
12.9% to 25.4% which underscores the need for better care for
these vulnerable women.  Significant challenges exist in the
care of these women – diabetic pregnancies are often
unrecognised, antenatal care facilities are often lacking,
materials for testing blood glucose are often not available, and
even insulin may be in short supply.  A more recent report
from Tanzania8 is more encouraging; here the PNM for 50
diabetic pregnancies was 10% despite the absence of home
blood glucose monitoring. 
The 2 unexplained maternal deaths in this study are of
concern.  Maternal mortality among pregnant diabetic women
in the UK is reported to vary between 0.1% and 0.5%.11
Between 1988 and 1999 there were 20 maternal deaths among
diabetic women in the UK from a total of 1 400 deaths, with
hypoglycaemia being a major cause of death.  
Caesarean section rates were high, which can be ascribed to
our reluctance to allow pregnancies to go beyond 38 weeks,
and the fact that 27% of women undergoing operative delivery
had had 1 or more prior caesarean sections.
Our patients with pregestational diabetes continue to present
late in pregnancy, largely as a result of the poor antenatal
services available to women in Soweto. Ideally, all diabetic
women should receive preconception counselling and care
with the aim of ensuring excellent glycaemic control before
and during pregnancy to prevent fetal morbidity and mortality
especially with regard to congenital anomalies. A recent meta-
analysis12 of 14 cohort studies has shown that preconception
care lowers the rate of major congenital anomalies from 6.5% to
2.1%.  This issue remains a challenge for us in Soweto.
The duration of diabetes in the type 1 DM group is relatively
short. This can be ascribed to the fact the age of onset for South
African black type 1 DM patients is about a decade later than
that of their white counterparts (median 22 years versus 10
years respectively).13 The GDM group clearly includes women
who have had previously undiagnosed pregestational diabetes.
This is supported by the fact that 95% of our GDM group
required insulin therapy, that 6 of these women had evidence
of diabetic retinopathy, that 1 had evidence of diabetic
nephropathy, and that 10 of the offspring had major congenital
abnormalities. 
Including women who did not return for postpartum OGTT,
26% of the GDM group had evidence of IGT (33%) or diabetes
(67%) postpartum.  Women with GDM have a considerably
increased risk of developing diabetes or IGT postpartum.  The
incidence is variable and is dependent on a number of factors,
e.g. the heterogeneity of the patient population studied, the
method used for diagnosing GDM in the previous pregnancy,
the length of follow-up postpartum, and the selection bias due
to incomplete follow-up.  In a recent review14 of the literature
the incidence varied from 10% to 64%.  Women with IGT
postpartum provide an opportunity for intervention.  Two
studies from different parts of the world have shown that with
lifestyle interventions such as diet, exercise and weight loss,
the development of type 2 DM in individuals with IGT can be
reduced by 58%.15,16 This is a challenge for us in the future.  
Comparison of 2 studies (Table V)
The methodologies used in the 2 studies (1983 - 19929 and 
1992 - 2002) were the same except for the measurement of
HbA1c which only became available from 1995 onwards. 
Therefore, the 2 studies reflect a combined experience of 1 087
diabetic pregnancies extending over 20 years.  Comparing the
2 studies, there has been a trend toward a reduction in PNM
from 6.1% to 3.7%, although this is not statistically significant 
(p = 0.06).  The combined PNM of 4.5% is considerably lower
than that of the combined ‘control’ groups of 19.9% 
(p < 0.001), and is also much lower than PNM figures from
studies conducted in other sub-Saharan African countries.4,5,7
Table V. Comparison of two studies
First study Second study
1983 - 19929 1992 - 2002
Pregnancies (N) 354 733
Perinatal mortality (%) 6.1 3.7
Major congenital 
abnormalities (N (%)) 6 (1.7) 11 (1.5)
Postpartum glucose 
intolerance (%) 34.6 25.9
Maternal mortality (N) 0 2
‘Control’ group 
perinatal mortality (%) 26 15.6
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There was no difference in postpartum glucose intolerance
(IGT or diabetes) between the 2 studies.  Combining the 2
studies, almost one-third (28.5%) of women had evidence of
glucose intolerance postpartum.  This is probably an
underestimate because a significant number of women did not
return for OGTT postpartum and long-term follow-up was not
possible.
Conclusion
These 2 studies indicate that the introduction of a specialised
service for pregnant diabetic women from a Third-World
community is both feasible and of benefit.  The measures
adopted were not particularly sophisticated or costly and
allowed for maximum ambulatory care.  The patients were
highly motivated, which made the education process easy and
follow-up reliable.  The diabetes nurse educator’s role was
pivotal in achieving the overall benefits associated with both
these studies.  Late referral/presentation of our patients
remains a vexing problem.  The relatively high incidence of
postpartum glucose intolerance stresses the importance of
postpartum follow-up.  The detection of IGT postpartum
provides an opportunity to institute preventive measures to
reduce the burden of diabetes.
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